{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:30:52Z","timestamp":1791901852220,"version":"4.3.4"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Division of Infection and Immunity"},{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Primary endpoint measures in clinical trials are typically measures of disease severity, with patient-reported outcome measures (PROMs) relegated as secondary endpoints. However, validation of some PROMs may be more rigorous than that of disease severity measures, which could provide support for a primary role for PROMs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study reports on 24 peer reviewed journal articles that used the Dermatology Life Quality Index (DLQI) as primary outcome, derived from a systematic review of randomized controlled trials (RCTs) utlizing DLQI, covering all diseases and interventions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study protocol was prospectively published on the PROSPERO database, and the study followed PRISMA guidelines. Searches were made using MEDLINE, The Cochrane Library, Embase, Web of Science, Scopus, CINAHL (EBSCO) and PsycINFO databases and records were combined into an Endnote database. Records were filtered for duplicates and selected based on study inclusion\/exclusion criteria. Full-text articles were sourced and data were extracted by two reviewers into a bespoke REDCap database, with a third reviewer adjudicating disagreements. The Jadad scoring method was used to determine risk of bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 3220 publications retrieved from online searching, 457 articles met the eligibility criteria and included 198 587 patients. DLQI scores were used as primary outcomes in 24 (5.3%) of these studies comprising 15 different diseases and 3436 patients. Most study interventions (17 of 24 studies, 68%) were systemic drugs, with biologics (liraglutide, alefacept, secukinumab, ustekinumab, adalimumab) accounting for 5 of 25 pharmacological interventions (20%). Topical treatments comprised 32% (8 studies), whereas nonpharmacological interventions (n = 8) were 24% of the total interventions (N = 33). Three studies used nontraditional medicines. Eight studies were multicentred (33.3%), with trials conducted in at least 14 different countries, and four studies (16.7%) were conducted in multiple countries. The Jadad risk of bias scale showed that bias was uncertain or low, as 87.5% of studies had Jadad scores of \u2265 3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study provides evidence for use of the DLQI as a primary outcome in clinical trials. Researchers and clinicians can use this data to inform decisions about further use of the DLQI as a primary outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae228","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T21:47:53Z","timestamp":1717192073000},"page":"497-507","source":"Crossref","is-referenced-by-count":18,"title":["The Dermatology Life Quality Index as the primary\u00a0outcome in randomized clinical trials: a\u00a0systematic review"],"prefix":"10.1093","volume":"191","author":[{"given":"Jeffrey R","family":"Johns","sequence":"first","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui","family":"Vyas","sequence":"additional","affiliation":[{"name":"Centre for Medical Education, School of Medicine, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz M","family":"Ali","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Salek","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire , Hatfield , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Y","family":"Finlay","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"2024091723523486400_ljae228-B1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cct.2004.09.003","article-title":"Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels","volume":"25","author":"Willke","year":"2004","journal-title":"Control Clin Trials"},{"key":"2024091723523486400_ljae228-B2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2022.07.013","article-title":"Clinical endpoints in trials of palliative radiotherapy: a systematic meta-research analysis","volume":"174","author":"Fabian","year":"2022","journal-title":"Radiother Oncol"},{"key":"2024091723523486400_ljae228-B3","author":"Finlay"},{"key":"2024091723523486400_ljae228-B4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/bjd\/ljad079","article-title":"A systematic review of 454 randomised controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries","volume":"190","author":"Vyas","year":"2023","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"2024091723523486400_ljae228-B5","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1093\/cid\/ciw317","article-title":"Patient-reported outcome assessments as endpoints in studies in infectious diseases","volume":"63","author":"Powers","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024091723523486400_ljae228-B6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-\u00adreported outcome (PRO) data from clinical trials: a systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"2024091723523486400_ljae228-B7","first-page":"61","article-title":"Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"key":"2024091723523486400_ljae228-B8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2024091723523486400_ljae228-B9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s41687-020-00219-4","article-title":"The impact of patient-\u00adreported outcome data from clinical trials: perspectives from international stakeholders","volume":"4","author":"Cruz Rivera","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2024091723523486400_ljae228-B10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1477-7525-11-83","article-title":"Potential of patient-\u00adreported outcomes as nonprimary endpoints in clinical trials","volume":"11","author":"Gnanasakthy","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"2024091723523486400_ljae228-B11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1191\/0962280204sm357ra","article-title":"Patient reported outcomes as endpoints in medical research","volume":"13","author":"Fairclough","year":"2004","journal-title":"Stat Methods Med Res"},{"key":"2024091723523486400_ljae228-B12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"2024091723523486400_ljae228-B13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-\u00adreported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"2024091723523486400_ljae228-B14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual Life Res"},{"key":"2024091723523486400_ljae228-B15","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-Outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"2024091723523486400_ljae228-B16","doi-asserted-by":"crossref","first-page":"e045105","DOI":"10.1136\/bmjopen-2020-045105","article-title":"SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials","volume":"11","author":"Calvert","year":"2021","journal-title":"BMJ Open"},{"key":"2024091723523486400_ljae228-B17","doi-asserted-by":"crossref","first-page":"n1367","DOI":"10.1136\/bmj.n1367","article-title":"Recommendations for including or reviewing patient reported outcome endpoints in grant applications","volume":"373","author":"Snyder","year":"2021","journal-title":"BMJ"},{"key":"2024091723523486400_ljae228-B18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jegh.2015.04.006","article-title":"Role of patient-\u00adreported outcomes and other efficacy endpoints in the drug approval process in Europe (2008\u20132012)","volume":"5","author":"Bansal","year":"2015","journal-title":"J Epidemiol Glob Health"},{"key":"2024091723523486400_ljae228-B19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO Extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"key":"2024091723523486400_ljae228-B20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM198606263142602","article-title":"The effects of antihypertensive therapy on the quality of life","volume":"314","author":"Croog","year":"1986","journal-title":"N Engl J Med"},{"key":"2024091723523486400_ljae228-B21","first-page":"25","article-title":"Squibb drug called superior in easing high blood pressure: findings of medical journal are leaked, prompting a jump in price of stock","author":"Bishop","year":"1986","journal-title":"Wall Street Journal"},{"key":"2024091723523486400_ljae228-B22","first-page":"e32-42","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024091723523486400_ljae228-B23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12885-019-5579-3","article-title":"Health-related quality of life as an endpoint in oncology phase I trials: a systematic review","volume":"19","author":"Fiteni","year":"2019","journal-title":"BMC Cancer"},{"key":"2024091723523486400_ljae228-B24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14694\/EdBook_AM.2012.32.80","article-title":"Capturing the patient perspective: patient-reported outcomes as clinical trial endpoints","author":"Bruner","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2024091723523486400_ljae228-B25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2024091723523486400_ljae228-B26","first-page":"790","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume-title":"IHRev Esp Cardiol (Engl Ed)","author":"Page","year":"2021"},{"key":"2024091723523486400_ljae228-B27","author":"Johns"},{"key":"2024091723523486400_ljae228-B28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","article-title":"PROSPERO: an international register of systematic review protocols","volume":"38","author":"Schiavo","year":"2019","journal-title":"Med Ref Serv Q"},{"key":"2024091723523486400_ljae228-B29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/02763869.2017.1259891","article-title":"Managing and coding references for systematic reviews and scoping reviews in EndNote","volume":"36","author":"Peters","year":"2017","journal-title":"Med Ref Serv Q"},{"key":"2024091723523486400_ljae228-B30","author":"Higgins"},{"key":"2024091723523486400_ljae228-B31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024091723523486400_ljae228-B32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/eurjcn\/zvab104","article-title":"Research Electronic Data Capture (REDCap): tackling data collection, management, storage, and privacy challenges","volume":"21","author":"Van Bulck","year":"2022","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2024091723523486400_ljae228-B33","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2024091723523486400_ljae228-B34","author":"Higgins"},{"key":"2024091723523486400_ljae228-B35","volume-title":"Evidence-based Obstetric Anesthesia","author":"Stephen","year":"2005"},{"key":"2024091723523486400_ljae228-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"2024091723523486400_ljae228-B37","doi-asserted-by":"crossref","first-page":"e17242","DOI":"10.1371\/journal.pone.0017242","article-title":"Applying the risk of bias tool in a systematic review of combination long-acting beta-\u00adagonists and inhaled corticosteroids for persistent asthma","volume":"6","author":"Hartling","year":"2011","journal-title":"PLOS ONE"},{"key":"2024091723523486400_ljae228-B38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1213\/ANE.0000000000002224","article-title":"Defining the primary outcomes and justifying secondary outcomes of a study: usually, the fewer, the better","volume":"125","author":"Vetter","year":"2017","journal-title":"Anesth Analg"},{"key":"2024091723523486400_ljae228-B39","volume-title":"Multiple Endpoints in Clinical Trials Guidance for Industry","author":"US Food and Drug Administration","year":"2022"},{"issue":"Suppl. 2","key":"2024091723523486400_ljae228-B40","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.jid.2017.07.140","article-title":"Validation of the electronic version of the Dermatology Life Quality Index (DLQI)","volume":"137","author":"Ali","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2024091723523486400_ljae228-B41","doi-asserted-by":"crossref","first-page":"e14039","DOI":"10.1111\/dth.14039","article-title":"Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: results of a clinical, multicenter, prospective study","volume":"33","author":"Campanati","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024091723523486400_ljae228-B42","first-page":"1","article-title":"Comparative effectiveness of purpuragenic 595 nm pulsed dye laser versus sequential emission of 595 nm pulsed dye laser and 1,064 nm Nd:YAG laser: a double-blind randomized controlled study","volume":"28","author":"Campos","year":"2019","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"2024091723523486400_ljae228-B43","doi-asserted-by":"crossref","first-page":"302","DOI":"10.36849\/JDD.5652","article-title":"Adding combined oral contraceptives or metformin to laser treatment in polycystic ovarian syndrome hirsute patients","volume":"20","author":"Dorgham","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"2024091723523486400_ljae228-B44","first-page":"335","article-title":"Randomized assessor-blinded controlled trial on the efficacy and safety of virgin coconut oil versus mineral oil as a therapeutic moisturizer for senile xerosis","volume":"53","author":"Escuadro-Chin","year":"2019","journal-title":"Acta Med. Philippina"},{"key":"2024091723523486400_ljae228-B45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/acm.2020.0343","article-title":"A comparison of the effect of topical preparation of Sambucus ebulus L. and hydrocortisone on hand eczema: a double-blind randomized controlled trial","volume":"27","author":"Farahani","year":"2021","journal-title":"J Altern Complement Med"},{"key":"2024091723523486400_ljae228-B46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients\u2014a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723523486400_ljae228-B47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2133.2004.05697.x","article-title":"Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis","volume":"150","author":"Feldman","year":"2004","journal-title":"Br J Dermatol"},{"key":"2024091723523486400_ljae228-B48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/hdi.12455","article-title":"Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial","volume":"21","author":"Foroutan","year":"2017","journal-title":"Hemodial Int"},{"key":"2024091723523486400_ljae228-B49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1468-3083.2011.04358.x","article-title":"Skin hardening effect in patients with polymorphic light eruption: comparison of UVB hardening in hospital with a novel home UV-hardening device","volume":"27","author":"Franken","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2024091723523486400_ljae228-B50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/09546634.2020.1746734","article-title":"Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life","volume":"31","author":"Gerdes","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2024091723523486400_ljae228-B51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ptr.2900","article-title":"Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial","volume":"24","author":"Grant","year":"2010","journal-title":"Phytother Res"},{"key":"2024091723523486400_ljae228-B52","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","article-title":"Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study","volume":"21","author":"Grimstad","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2024091723523486400_ljae228-B53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1468-3083.2007.02385.x","article-title":"Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study","volume":"22","author":"Grob","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2024091723523486400_ljae228-B54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1398-9995.2008.01913.x","article-title":"How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life","volume":"64","author":"Grob","year":"2009","journal-title":"Allergy"},{"key":"2024091723523486400_ljae228-B55","doi-asserted-by":"crossref","first-page":"e14522","DOI":"10.1111\/dth.14522","article-title":"Comparison of gabapentin and doxepin in the management of uremic pruritus: a randomized crossover clinical trial","volume":"33","author":"Haber","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024091723523486400_ljae228-B56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/phpp.12065","article-title":"A quantitative assessment of the effects of formal sun protection education on photosensitive patients","volume":"29","author":"Huang","year":"2013","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2024091723523486400_ljae228-B57","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s13555-021-00545-5","article-title":"Dermatology Life Quality Index in patients with moderate-to-severe plaque psoriasis treated with brodalumab or ustekinumab","volume":"11","author":"Lambert","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024091723523486400_ljae228-B58","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091346","article-title":"A new approach to atopic dermatitis control with low-concentration propolis-loaded cold cream","volume":"13","author":"Martin","year":"2021","journal-title":"Pharmaceutics"},{"key":"2024091723523486400_ljae228-B59","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/bmj.38670.494734.7C","article-title":"Evaluation of a general practitioner with special interest service for dermatology: randomised controlled trial","volume":"331","author":"Salisbury","year":"2005","journal-title":"BMJ"},{"key":"2024091723523486400_ljae228-B60","first-page":"865","article-title":"Topical turmeric microemulgel in the management of plaque psoriasis; a clinical evaluation","volume":"14","author":"Sarafian","year":"2015","journal-title":"Iran J Pharm Res"},{"key":"2024091723523486400_ljae228-B61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2340\/00015555-1697","article-title":"Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: a pragmatic randomised controlled trial","volume":"94","author":"Schmitt","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"2024091723523486400_ljae228-B62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01474","article-title":"The efficacy and safety of a fixed combination of Chinese herbal medicine in chronic urticaria: a randomized, double-blind, placebo-controlled pilot study","volume":"9","author":"Yang","year":"2018","journal-title":"Front Pharmacol"},{"key":"2024091723523486400_ljae228-B63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024091723523486400_ljae228-B64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpainsymman.2008.02.007","article-title":"Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer","volume":"37","author":"Eckhardt","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"2024091723523486400_ljae228-B65","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.17109","article-title":"Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic \u00adtherapy-na\u00efve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial","volume":"35","author":"Tha\u00e7i","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723523486400_ljae228-B66","first-page":"264","article-title":"Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers","volume":"6","author":"Zagadailov","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"2024091723523486400_ljae228-B67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s41687-022-00529-9","article-title":"Assessing the collection and reporting of patient-reported outcome data in interventional cancer trials: a single institution, retrospective systematic evaluation","volume":"6","author":"Lidington","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2024091723523486400_ljae228-B68","doi-asserted-by":"crossref","first-page":"10134","DOI":"10.3389\/ti.2022.10134","article-title":"Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions","volume":"35","author":"Tong","year":"2022","journal-title":"Transpl Int"},{"key":"2024091723523486400_ljae228-B69","doi-asserted-by":"crossref","first-page":"1542920","DOI":"10.1080\/20016689.2018.1542920","article-title":"Patient-reported outcome claims in European and United States orphan drug approvals","volume":"6","author":"Jaroslawski","year":"2018","journal-title":"J Mark Access Health Policy"},{"issue":"Suppl. 4","key":"2024091723523486400_ljae228-B70","first-page":"P82","article-title":"Validation of the Dermatology Life Quality Index (DLQI): a systematic review of the literature","volume":"188","author":"Vyas","year":"2024","journal-title":"Br J Dermatol"},{"key":"2024091723523486400_ljae228-B71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size\u2014or why the P value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J Grad Med Educ"},{"key":"2024091723523486400_ljae228-B72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2024091723523486400_ljae228-B73","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2024091723523486400_ljae228-B74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"2024091723523486400_ljae228-B75","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2340\/00015555-2894","article-title":"Two minimal clinically important difference (2MCID): a new twist on an old concept","volume":"98","author":"Ali","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2024091723523486400_ljae228-B76","volume-title":"Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"US Food and Drug Administration","year":"2009"},{"key":"2024091723523486400_ljae228-B77","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"Br J Dermatol"},{"key":"2024091723523486400_ljae228-B78","author":"Cardiff University"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae228\/58657581\/ljae228.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/497\/59122460\/ljae228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/497\/59122460\/ljae228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T23:53:00Z","timestamp":1726617180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/4\/497\/7685843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":78,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,31]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae228","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,31]]}}}